$11 billion drugmaker Mylan and US drug giant Pfizer are teaming up to reshape Mylan’s business. 3 tough questions from Wall Street analyst show the challenging road ahead.

📆 29.07.2019 23:48:00
📰 BusinessInsider

⏱ Reading Time:
18 sec. here
2 min. at publisher
📊 Quality Score:
News: 11%
Publisher: 51%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

Wall Street analysts asked big questions about the new company's future. Execs occasionally got testy.

Three tough questions from Wall Street analysts on a Monday conference call show why the spinoff could face an uphill battle.

A major deal announced on Monday will combine generic drugmaker Mylan with a unit of Pfizer that makes off-patent products like Viagra., best known for making the EpiPen allergy shot. Mylan's shares have lost almost half their value over the past year, though they surged 14% on Monday after the deal was announced. Pfizer's stock fell 2%.

Написать комментарий

Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

Fewer investors have a 'fear of missing out,' so it may be time to buckle up, market bull suggestsOppenheimer Asset Management's John Stoltzfus expects wave of volatility to pressure stocks due to uncertainty. FuturesNow ohh it's going to be a a good dump for sure!
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »